A Phase I, Open-label, Cohort Dose Escalation Trial With BI 836858 in Patients With Refractory or Relapsed Acute Myeloid Leukemia and Patients With Acute Myeloid Leukemia in Complete Remission With High Risk to Relapse
Phase of Trial: Phase I
Latest Information Update: 24 Dec 2017
At a glance
- Drugs BI 836858 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 27 Nov 2017 Planned End Date changed from 25 Mar 2019 to 25 Mar 2020.
- 27 Nov 2017 Planned primary completion date changed from 25 Mar 2019 to 25 Mar 2020.
- 22 Feb 2017 Planned number of patients changed from 36 to 63.